Fungal infections represent an escalating global health challenge, with rising prevalence and antifungal resistance significantly complicating patient management. The World Health Organization (WHO) has identified Candida bloodstream infections (candidemia) as high risk in its Fungal Priority Pathogens List due to their elevated infection and mortality rates.
This feasibility study of the LifeScale rAFST system indicates that a rapid testing approach has the potential to significantly enhance clinical decision-making in the management of invasive fungal infections. By delivering same-day antifungal susceptibility results—as opposed to the two days or more required by current methods—rapid technologies can enable more timely, targeted interventions.
Overall, the streamlined workflow of the LifeScale rAFST system supports earlier treatment adjustments, representing a meaningful advancement in patient care and antifungal stewardship.
